Table 2.

Clinical and laboratory characteristics of 626 primary (de novo) and 497 secondary (post-myeloid and therapy related) acute myeloid leukemia (non-APL) patients with complete cytogenetic findings.

Variable	Primary (de novo) AML, n = 626	Secondary (post-myeloid and therapy related) AML, n = 497	p value
Age (years), median (range)	62 (18.7–92)	67 (18–94)	<0.0001
Age groups
<60 years	275 (44)	129 (26)	<0.0001
≥60 years	351 (56)	368 (74)
Gender
Male	364 (58)	325 (65)	0.01
Female	262 (42)	172 (35)
Year of diagnosis
2004–2010	274 (44)	175 (35)	0.004
2011–2017	352 (56)	322 (65)
Leukocyte ×109/L median (range)	8.6 (0.3–350)	4.5 (0.1–246)	<0.0001
Platelets ×109/L median (range)	64 (3–1550)	50 (2.6–1149)	0.0002
Peripheral blood blast, % median (range)	24 (0–131)	14 (0–99)	<0.0001
Bone marrow blast, % median (range)	60 (0–99)	34 (0–99)	<0.0001
European LeukemiaNet
Favorable	39 (6)	8 (2)	<0.0001
Intermediate	419 (67)	231 (46)
Adverse	168 (27)	258 (52)
Molecular (genetic) findings (n = 392)
FLT3-ITD and NPM1 negative	133 (56)	123 (80)	<0.0001
FLT3-ITD negative and NPM1 positive	47 (20)	20 (13)
FLT3-ITD and NPM1 positive	33 (14)	6 (4)
FLT3-ITD positive and NPM1 negative	25 (10)	5 (3)
Type of therapy
Intensive (induction) therapy	484 (77)	282 (57)	<0.0001
Hypomethylating agents	60 (10)	84 (17)
No therapy	82 (13)	131 (26)
Induction therapy outcome (n = 763)
Complete remission (CR)	249 (52)	84 (30)	<0.0001
CR with incomplete hematologic recovery (CRi)	148 (31)	100 (35)
No remission	84 (17)	98 (35)
Stem cell transplant (n = 1118)
Yes	163 (26)	98 (20)	0.01
No	460 (74)	397 (80)
Deaths	418 (67)	397 (80)	<0.0001
Median survival, months (range)	27.9 (22–35)	9.2 (7.7–11)	<0.0001

Bold values indicates the variable to describe primary and secondary AML including their p values.